ABIONYX Pharma Declares Approvals Of Key Resolutions At Combined General Conference

ABIONYX Pharma, a biotech company focused on developing innovative therapies using the world’s only natural recombinant apoA-I, announced the approval of all resolutions at its Combined General Meeting held on November 28, 2024.

Critical resolutions included the appointment of Jean-Gérard Galvez, Luc Demarre, and Caroline DeSurmont as directors for a four-year term. With these appointments, the Board now consists of three women among its eight members, meeting regulatory requirements, and features four independent directors.

Shareholders also approved financial delegations essential for the company's development and amendments to the bylaws. It includes statutory threshold declaration rules, an extension of the director's term, and the introduction of double voting rights.

ABIONYX Pharma thanked its shareholders for taking part and supporting the company through various voting methods. The minutes of the meeting, the results of the vote, and a replay of the session are available in the Shareholder Meeting section on the company's website.